LPH-48 is a selective serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of alcoholism.[1][2][3] Its route of administration has not been specified.[1]
| Clinical data | |
|---|---|
| Other names | LPH48 |
| Routes of administration | Unspecified[1] |
| Drug class | Selective serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen[1][2] |
The drug acts as a selective agonist of the serotonin 5-HT2A receptor.[1][2][3] It is said to be an analogue of LPH-5 with similar characteristics but with faster metabolism and a shorter duration of action.[3] LPH-5 is a highly selective serotonin 5-HT2A receptor agonist that is under development for major depressive disorder and has shown antidepressant-like effects in animals.[4][5][6]
LPH-48 is under development by Lophora.[1][2] As of May 2024, it is in preclinical research for alcoholism.[1][2] The chemical structure of LPH-48 does not yet seem to have been disclosed.[1] However, Lophora has patented selective serotonin 5-HT2A receptor agonists for treatment of depression[7] and the company is said to have patent protection for LPH-48.[1] Additionally, the structure of its close analogue LPH-5 is known and this compound is a phenylpiperidine derivative.[4]
See also
editReferences
edit- ^ a b c d e f g h i "LPH 48". AdisInsight. 22 May 2024. Retrieved 30 October 2024.
LPH 48 is a ligand therapeutic which has a similar pharmacological profile as psilocybin with superior selectivity and shorter duration, being developed by [...]
- ^ a b c d e "Delving into the Latest Updates on LPH-48 with Synapse". Synapse. 19 September 2024. Retrieved 30 October 2024.
- ^ a b c Lophora (31 May 2024). "Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for Lead CNS Drug LPH-5" (PDF). Retrieved 30 October 2024.
About LPH-48: LPH-48 is a shorter acting direct analog of LPH-5 with similar optimized characteristics and safety profile, but with a shorter duration of action. LPH-48 is designed as a fast-follower that shows significantly faster metabolism, indicating a shorter duration of action in man. LPH-48 is a representative of the same proprietary compound class as LPH-5 and is therefore endowed with the same optimized characteristics including favorable drug-like properties and a safe pharmacological profile.
- ^ a b M Ro Rsted E, Jensen AA, Smits G, Frydenvang K, Kristensen JL (May 2024). "Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists". Journal of Medicinal Chemistry. 67 (9): 7224–7244. doi:10.1021/acs.jmedchem.4c00082. PMC 11089506. PMID 38648420.
- ^ "LPH 5". AdisInsight. 7 March 2023. Retrieved 30 October 2024.
- ^ Jensen AA, Cecchi CR, Hibicke M, Bach AH, Kaadt E, Märcher-Rørsted E, et al. (22 April 2024), The selective 5-HT2Areceptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents, Cold Spring Harbor Laboratory, doi:10.1101/2024.04.19.590212
- ^ WO 2021/089824, Kristensen JL, Jensen AA, Märcher-Rørsted E, Leth-Petersen S, "5-HT2A agonists for use in treatment of depression", published 14 May 2021, assigned to Lophora ApS
External links
edit | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |